Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PSCK9) is secreted mainly from the liver and binds to the low-density lipoprotein receptor (LDLR), reducing LDLR availability and thus resulting in an increase in LDL-cholesterol. While the LDLR has been implicated in the cell entry process...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramanathan, Aarti, Gusarova, Viktoria, Stahl, Neil, Gurnett-Bander, Anne, Kyratsous, Christos A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845998/
https://www.ncbi.nlm.nih.gov/pubmed/27115873
http://dx.doi.org/10.1371/journal.pone.0154498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845998/
https://www.ncbi.nlm.nih.gov/pubmed/27115873
http://dx.doi.org/10.1371/journal.pone.0154498

Ejemplares similares